Switch theme
Sign up to access all valuation multiples
Acepodia Inc is a clinical stage biotechnology company engaged to develop innovative highly effective first-in-class cell therapies by using Antibody-Cell Conjugation platform technology for cancer that are broadly accessible for patients.
2017
n/a
LTM Revenue n/a
LTM EBITDA n/a
$192M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Acepodia has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Acepodia achieved revenue of $0.5M and an EBITDA of -$23.2M.
Acepodia expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Acepodia valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | $0.5M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$42.1M | -$23.2M | XXX | XXX | XXX |
| EBITDA Margin | NaN% | -4607% | XXX | XXX | XXX |
| Net Profit | -$26.6M | -$42.9M | XXX | XXX | XXX |
| Net Margin | NaN% | -8524% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of March 17, 2025, Acepodia's stock price is TWD 22 (or $1).
Acepodia has current market cap of TWD 12.3B (or $374M), and EV of TWD 6.3B (or $192M).
See Acepodia trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $192M | $374M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of March 17, 2025, Acepodia has market cap of $374M and EV of $192M.
Acepodia's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Acepodia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Acepodia and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $192M | XXX | XXX | XXX |
| EV/Revenue | 380.9x | XXX | XXX | XXX |
| EV/EBITDA | -8.3x | XXX | XXX | XXX |
| P/E | -15.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -13.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAcepodia's NTM/LTM revenue growth is n/a
Acepodia's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Acepodia's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Acepodia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Acepodia and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | -4607% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -45% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 854% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1874% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 2727% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Acepodia acquired XXX companies to date.
Last acquisition by Acepodia was XXXXXXXX, XXXXX XXXXX XXXXXX . Acepodia acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Acepodia founded? | Acepodia was founded in 2017. |
| Where is Acepodia headquartered? | Acepodia is headquartered in Taiwan. |
| Is Acepodia publicy listed? | Yes, Acepodia is a public company listed on ROCO. |
| What is the stock symbol of Acepodia? | Acepodia trades under 6976 ticker. |
| When did Acepodia go public? | Acepodia went public in 2023. |
| Who are competitors of Acepodia? | Similar companies to Acepodia include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Acepodia? | Acepodia's current market cap is $374M |
| Is Acepodia profitable? | Yes, Acepodia is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
